The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis

We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to deterioration in both Ambulation Index and Kurtzke Expanded Disability Status Scale score. This study confirms a modest therapeutic benefit for azathioprine previously reported by other investigators.

[1]  British And Dutch Multiple Sclerosis Azathioprine Trial Group.  DOUBLE-MASKED TRIAL OF AZATHIOPRINE IN MULTIPLE SCLEROSIS , 1988, The Lancet.

[2]  L. Kinlen.  Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.

[3]  F. Lhermitte,et al.  NOT SO BENIGN LONG-TERM IMMUNOSUPPRESSION IN MULTIPLE SCLEROSIS? , 1984, The Lancet.

[4]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[5]  H. Weiner,et al.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.

[6]  G. Ellison,et al.  A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis , 1978, Neurology.

[7]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[8]  Immunological Treatment in Multiple Sclerosis , 1980, The Lancet.

[9]  A. Compston,et al.  DOUBLE-BLIND CONTROLLED TRIAL OF IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSIS: FINAL REPORT , 1982, The Lancet.

[10]  M. Nuwer,et al.  Clinical experience with azathioprine: The pros , 1988, Neurology.

[11]  H. Weiner,et al.  MS: a CNS and systemic autoimmune disease. , 1989, Immunology today.

[12]  M. R. Mickey,et al.  A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis , 1989, Neurology.